Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial-Reference-Cited by-同舟云学术

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

Published:2006-03 Issue:3 Volume:17 Page:409-414
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Coudert B.P.,Arnould L.,Moreau L.,Chollet P.,Weber B.,Vanlemmens L.,Moluçon C.,Tubiana N.,Causeret S.,Misset J.-L.,Feutray S.,Mery-Mignard D.,Garnier J.,Fumoleau P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/3/409/341063/mdj096.pdf

Reference26 articles.

1. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis;Mauri;J Natl Cancer Inst,2005

2. Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint;Kurosumi;Breast Cancer,2004

3. Amplification of a novel v-erbB-related gene in a human mammary carcinoma;King;Science,1985

4. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30

2. Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab;Frontiers in Oncology;2022-03-04

3. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial);European Journal of Cancer;2021-11

4. Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World;Frontiers in Oncology;2021-07-28

5. Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer;European Journal of Clinical Pharmacology;2021-07-10